EA201270730A1 - ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕ - Google Patents
ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕInfo
- Publication number
- EA201270730A1 EA201270730A1 EA201270730A EA201270730A EA201270730A1 EA 201270730 A1 EA201270730 A1 EA 201270730A1 EA 201270730 A EA201270730 A EA 201270730A EA 201270730 A EA201270730 A EA 201270730A EA 201270730 A1 EA201270730 A1 EA 201270730A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- methods
- cdc7
- dihydrogranaticin
- inhibit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B13/00—Oxyketone dyes
- C09B13/02—Oxyketone dyes of the naphthalene series, e.g. naphthazarin
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B61/00—Dyes of natural origin prepared from natural sources, e.g. vegetable sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
Изобретение относится к соединениям, способам, фармацевтическим композициям и наборам для лечения пролиферативных нарушений, таких как злокачественная опухоль. В одном аспекте способы предусматривают соединения, которые ингибируют активность протеинкиназ, таких как киназа клеточного цикла (Cdc). В другом аспекте способы предусматривают соединения, которые ингибируют активность Cdc7 и/или Dbf4. В другом аспекте способы предусматривают соединения, которые проявляют антипролиферативные свойства, применимые в лечении заболеваний, таких как злокачественная опухоль. Соединения, применимые для какого-либо из способов, включают соединения формулы (А) или (В) или их фармацевтически приемлемые соли. Типичные соединения формулы (А) или (В) включают гранатицин А, гранатицин В, дигидрогранатицин А, дигидрогранатицин В, медермицин и актинорходин.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31174110P | 2010-03-08 | 2010-03-08 | |
PCT/US2011/027619 WO2011112635A1 (en) | 2010-03-08 | 2011-03-08 | Cdc7 kinase inhibitors and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201270730A1 true EA201270730A1 (ru) | 2013-02-28 |
EA025443B1 EA025443B1 (ru) | 2016-12-30 |
Family
ID=43903897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201270730A EA025443B1 (ru) | 2010-03-08 | 2011-03-08 | ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА КИНАЗЫ Cdc7 ГРАНАТИЦИНА B |
Country Status (12)
Country | Link |
---|---|
US (7) | US9180105B2 (ru) |
EP (3) | EP2544674B1 (ru) |
JP (1) | JP5827962B2 (ru) |
CN (1) | CN102844023B (ru) |
AU (1) | AU2011224457B2 (ru) |
CA (1) | CA2789484C (ru) |
DK (1) | DK2544674T3 (ru) |
EA (1) | EA025443B1 (ru) |
ES (1) | ES2661367T3 (ru) |
HK (1) | HK1257444A1 (ru) |
TR (1) | TR201800962T4 (ru) |
WO (1) | WO2011112635A1 (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1583562B1 (en) | 2003-01-06 | 2011-06-15 | Angiochem Inc. | Angiopep-1, related compounds, and uses thereof |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
TR201905480T4 (tr) | 2008-04-18 | 2019-05-21 | Angiochem Inc | Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri. |
CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
EP2346896A4 (en) | 2008-10-15 | 2014-06-25 | Angiochem Inc | CONJUGATES OF ETOPOSIDE AND DOXORUBICIN FOR THE ADMINISTRATION OF MEDICAMENTS |
BRPI0922689A2 (pt) | 2008-12-05 | 2018-11-06 | Angiochem Inc. | conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos |
CN102300987A (zh) | 2008-12-17 | 2011-12-28 | 安吉奥开米公司 | 膜型-1基质金属蛋白抑制剂及其用途 |
RU2011146654A (ru) | 2009-04-20 | 2013-05-27 | Ангиокем Инк. | Способы лечения рака яичников с применением конъюгированного средства |
IN2012DN00248A (ru) | 2009-07-02 | 2015-05-01 | Angiochem Inc | |
CN102844023B (zh) * | 2010-03-08 | 2016-01-20 | 索隆-基特林癌症研究协会 | Cdc7激酶抑制剂以及其用途 |
RU2019107011A (ru) * | 2014-01-24 | 2019-04-08 | Лэм Терапьютикс, Инк. | Композиции апилимода и способы их применения |
EP3100742B1 (en) | 2014-01-31 | 2020-05-20 | Carna Biosciences Inc. | Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor |
CN103980285B (zh) * | 2014-06-06 | 2016-03-16 | 中国医学科学院医药生物技术研究所 | 一种吡喃萘醌类抗生素及其制备和应用 |
US10206910B2 (en) | 2014-11-07 | 2019-02-19 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
AU2015369707B2 (en) | 2014-12-23 | 2020-07-23 | Sloan-Kettering Institute For Cancer Research | Polymorph of granaticin B |
CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
KR20170054190A (ko) * | 2015-11-09 | 2017-05-17 | (주)앰틱스바이오 | 진균 감염 치료 및 예방을 위한 신규한 키나아제 및 이들의 용도 |
US10919896B2 (en) * | 2016-09-22 | 2021-02-16 | Cancer Research Technology Limited | Preparation and uses of pyrimidinone derivatives |
WO2018158898A1 (en) * | 2017-03-01 | 2018-09-07 | Takeda Pharmaceutical Company Limited | Method of predicting effects of cdc7 inhibitor |
CN107349199A (zh) * | 2017-07-18 | 2017-11-17 | 华北制药集团新药研究开发有限责任公司 | 榴菌素类化合物的医药用途 |
CN107903277B (zh) * | 2017-10-18 | 2019-09-20 | 浙江大学 | 一种n-甲基-美达霉素类化合物及其制备方法和应用 |
GB201807147D0 (en) | 2018-05-01 | 2018-06-13 | Oncologica Uk Ltd | Therapeutic combination |
NL2021185B1 (en) * | 2018-06-26 | 2020-01-06 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Combination Therapy and Use Thereof for Treating Cancer |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH476102A (de) * | 1966-02-22 | 1969-07-31 | Ciba Geigy | Verfahren zur Herstellung eines neuen Antibiotikums |
GB1184422A (en) * | 1966-02-22 | 1970-03-18 | Ciba Ltd | Antibiotic Granaticin B and Process for its Manufacture |
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5593970A (en) * | 1990-06-11 | 1997-01-14 | Biochem Pharma Inc. | Heterocyclic anthracycline analogs |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
DE4121468A1 (de) * | 1991-06-28 | 1993-01-14 | Deutsches Primatenzentrum Gmbh | Antivirale substanzen und diese enthaltende arzneimittel |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
JP2001506172A (ja) | 1997-07-22 | 2001-05-15 | イーメッド コーポレイション | 作用物質のイオン導入法による送達のための針 |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
CA2335115C (en) * | 1998-06-16 | 2009-01-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fused azepinone cyclin dependent kinase inhibitors |
US20010047032A1 (en) | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
JP4457211B2 (ja) * | 2004-02-03 | 2010-04-28 | 学校法人慶應義塾 | ナフトキノン誘導体化合物又はその薬理学的に許容される塩、並びに、それらを有効成分として含有するCdc25ホスファターゼ阻害剤及び抗腫瘍剤 |
CN102844023B (zh) | 2010-03-08 | 2016-01-20 | 索隆-基特林癌症研究协会 | Cdc7激酶抑制剂以及其用途 |
AU2015369707B2 (en) | 2014-12-23 | 2020-07-23 | Sloan-Kettering Institute For Cancer Research | Polymorph of granaticin B |
-
2011
- 2011-03-08 CN CN201180012863.5A patent/CN102844023B/zh active Active
- 2011-03-08 EP EP11709276.7A patent/EP2544674B1/en active Active
- 2011-03-08 TR TR2018/00962T patent/TR201800962T4/en unknown
- 2011-03-08 DK DK11709276.7T patent/DK2544674T3/da active
- 2011-03-08 CA CA2789484A patent/CA2789484C/en active Active
- 2011-03-08 WO PCT/US2011/027619 patent/WO2011112635A1/en active Application Filing
- 2011-03-08 AU AU2011224457A patent/AU2011224457B2/en active Active
- 2011-03-08 JP JP2012557185A patent/JP5827962B2/ja active Active
- 2011-03-08 EP EP23150649.4A patent/EP4201402A1/en active Pending
- 2011-03-08 ES ES11709276.7T patent/ES2661367T3/es active Active
- 2011-03-08 US US13/583,170 patent/US9180105B2/en active Active
- 2011-03-08 EP EP17198166.5A patent/EP3338770B1/en active Active
- 2011-03-08 EA EA201270730A patent/EA025443B1/ru not_active IP Right Cessation
-
2015
- 2015-11-09 US US14/936,472 patent/US9492427B2/en active Active
-
2016
- 2016-11-11 US US15/349,905 patent/US9782386B2/en active Active
-
2017
- 2017-10-10 US US15/728,609 patent/US10123992B2/en active Active
-
2018
- 2018-11-13 US US16/189,780 patent/US11045446B2/en active Active
- 2018-12-27 HK HK18116679.4A patent/HK1257444A1/zh unknown
-
2021
- 2021-05-26 US US17/330,957 patent/US11666550B2/en active Active
-
2023
- 2023-04-24 US US18/138,351 patent/US20230255929A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TR201800962T4 (en) | 2018-03-21 |
AU2011224457A1 (en) | 2012-09-20 |
EP3338770A1 (en) | 2018-06-27 |
CA2789484C (en) | 2019-10-22 |
US9782386B2 (en) | 2017-10-10 |
EP3338770B1 (en) | 2023-06-07 |
US20230255929A1 (en) | 2023-08-17 |
US20210283099A1 (en) | 2021-09-16 |
US11045446B2 (en) | 2021-06-29 |
CA2789484A1 (en) | 2011-09-15 |
US11666550B2 (en) | 2023-06-06 |
US20130035301A1 (en) | 2013-02-07 |
HK1257444A1 (zh) | 2019-10-18 |
CN102844023B (zh) | 2016-01-20 |
JP5827962B2 (ja) | 2015-12-02 |
EP2544674A1 (en) | 2013-01-16 |
US20160058733A1 (en) | 2016-03-03 |
JP2013522212A (ja) | 2013-06-13 |
ES2661367T3 (es) | 2018-03-28 |
EA025443B1 (ru) | 2016-12-30 |
WO2011112635A1 (en) | 2011-09-15 |
AU2011224457B2 (en) | 2014-11-06 |
US9492427B2 (en) | 2016-11-15 |
US10123992B2 (en) | 2018-11-13 |
US20190314329A1 (en) | 2019-10-17 |
EP2544674B1 (en) | 2017-10-25 |
DK2544674T3 (da) | 2018-01-29 |
US20170119731A1 (en) | 2017-05-04 |
US20180125815A1 (en) | 2018-05-10 |
US9180105B2 (en) | 2015-11-10 |
EP4201402A1 (en) | 2023-06-28 |
CN102844023A (zh) | 2012-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201270730A1 (ru) | ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕ | |
CY1121882T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
CY1124068T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
CY1120866T1 (el) | Παρεμποδιστες dna-pk | |
EA201491356A1 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
EA201391682A1 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
CY1117424T1 (el) | Βενζοδιαζεπινικος αναστολεας bromodomain | |
EA201101497A1 (ru) | Имидазопираны для применения в качестве ингибиторов киназ | |
EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
EA201400707A1 (ru) | Дизамещенные бензотиенил-пирролотриазины и их применение в качестве ингибиторов киназы рфрф | |
EA202090291A3 (ru) | Производные бипиразола в качестве ингибиторов jak | |
EA201101583A1 (ru) | Ингибиторы pi3 киназы или mtor | |
EA201590230A1 (ru) | Соединения пиразолопиримидина в качестве ингибиторов киназ | |
EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
EA201391285A1 (ru) | Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена | |
EA201300080A1 (ru) | Дипиридильные производные, пригодные для лечения заболеваний, индуцированных киназами | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
EA201290980A1 (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
EA201270373A1 (ru) | Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли | |
EA201100580A1 (ru) | Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
EA201201161A1 (ru) | Пирролопиримидины в качестве ингибиторов cdk4/6 | |
EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |